The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 31, 2026 for Docon Technologies Pvt Ltd

Docon Technologies Private Limited, promoter of Thyrocare Technologies, has disclosed an update regarding encumbrance on its 9,69,69,696 shares (60.93% stake) in Thyrocare. The update follows partial redemption of Series 1 Non-Convertible Debentures by API Holdings Limited (Docon's parent company) aggregating INR 1,200 million on March 30, 2026. The face value per debenture was reduced from INR 10,00,000 to INR 9,00,000. Critically, there is NO change in the number of encumbered shares of Thyrocare held by Docon - all 60.93% remain pledged with Catalyst Trusteeship Limited as security for the debentures. The disclosure primarily updates the list of debenture holders and outstanding principal details to reflect the current position. The debenture holders include 360 One Prime Limited, Micro Labs Limited, Tata Capital Limited, and several others, with total debenture value now at INR 10,800 million post-reduction.